



HAL
open science

Glucagon-like peptide-1 secretagogues from the leaves of *Oparanthus teikiteetini*

Clément Huguet, Opeyemi Joshua Olatunji, Eleonore Real, Phila
Raharivelomanana, Aurelie A. Urbain

► To cite this version:

Clément Huguet, Opeyemi Joshua Olatunji, Eleonore Real, Phila Raharivelomanana, Aurelie A. Urbain. Glucagon-like peptide-1 secretagogues from the leaves of *Oparanthus teikiteetini*. *Phytochemistry Letters*, 2019, 30, pp.201-204. 10.1016/j.phytol.2019.02.020 . hal-02271738

HAL Id: hal-02271738

<https://hal.science/hal-02271738v1>

Submitted on 13 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Glucagon-like peptide-1 secretagogues from the leaves of *Oparanthus teikiteetini*

Clément Huguet^a, Opeyemi Joshua Olatunji^{a1}, Eleonore Real^b, Phila Raharivelomanana^c, Aurélie Urbain^{a*}

^a Université de Strasbourg, CNRS, IPHC UMR 7178, 67000 Strasbourg, France

^b Université de Strasbourg, CNRS, LBP UMR 7021, 67000 Strasbourg, France

^c Université de Polynésie française, EIMS UMR 241 EIO, 98702 Faa'a Tahiti, French Polynesia

*Corresponding author at:

Postal address: Chimie Analytique des Molécules Bioactives et Pharmacognosie, UMR 7178, Faculté de Pharmacie, Université de Strasbourg, 74 route du Rhin, CS 60024, 67401 Illkirch Cedex, France

E-mail address: urbain@unistra.fr

Tel: +33 368 85 41 80

Abstract

In our search for natural compounds that stimulate glucagon-like peptide-1 secretion, an extract from the leaves of *Oparanthus teikiteetini* (Asteraceae) was found to increase significantly GLP-1 secretion *in vitro* in a model cell line (mouse intestinal STC-1 cells). The phytochemical investigation of this extract resulted in the isolation of two new dihydrobenzofuran derivatives (**1-2**) identified as (2R)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-5-ol (**1**) and (2S,3R)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-3,5-diol (**2**). Thirteen other compounds were isolated, including eight known dihydrobenzofuran derivatives (**3-10**), jasopyran (**11**), and four sesquiterpene lactones (**12-15**) including a new one, grandulin (**15**). Their structures were established mainly by NMR and HRESIMS analysis and by comparison with data reported in the literature. Tested on STC-1 cells at the concentration of 100 μ M, compounds **7**, **11**, and **12** increased GLP-1 secretion by 305, 218, and 156% respectively, compared to control cells, without affecting cell viability.

Keywords: *Oparanthus teikiteetini*; benzofuran derivatives; coumaran; sesquiterpene lactones; glucagon-like peptide-1 secretion

¹ Present address : Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai 90112, Thailand

1. Introduction

Oparanthus teikiteetini (J.Florence & Stuessy) R.K.Shannon & W.L.Wagner is a tree endemic to the Marquesas Islands, French Polynesia, which belongs to the Asteraceae family and to the subtribe Coreopsidinae. Firstly described under the genus *Bidens* (Florence and Stuessy, 1988), it has been recently revised to the genus *Oparanthus* (Ryding and Bremer, 1992; Shannon and Wagner, 1997). No traditional uses have been reported for this species that has been found only in the restricted area of the Toovi plateau on the island of Nuku Hiva, and no phytochemical nor pharmacological studies have been conducted until now. According to phylogenetic trees, *O. teikiteetini* is rather closely-related to *Fitchia speciosa*, endemic to the Cook Islands (Kimball and Crawford, 2004). This latter species was found to contain mainly sesquiterpene lactones, as most of the Asteraceae, and dihydrobenzofuran derivatives (Bohlmann et al., 1980). As part of our continuous efforts to identify natural GLP-1 secretagogues, we decided to evaluate the potential of *O. teikiteetini* to stimulate the secretion of glucagon-like peptide-1 (GLP-1) *in vitro* in a mouse intestinal cell culture model. GLP-1 is an intestinally secreted peptide involved in blood glycemia regulation (Nicolaus et al., 2011). As its secretion is impaired in patients with type 2 diabetes, compounds improving GLP-1 secretion levels could therefore represent a novel therapeutic strategy (Nauck et al., 1993; Nauck et al., 1997; Vilsbøll et al., 2001). In our *in vitro* assay, the EtOAc extract from the leaves of *O. teikiteetini* increased significantly the extracellular secretion of GLP-1 in STC-1 cells. The phytochemical investigation of this extract led to the isolation of 15 compounds, including mainly benzofuran and benzopyran derivatives (**1-11**), together with 4 sesquiterpenoids (**12-15**). All compounds were evaluated for GLP-1 secretagogue activity and some of them (**7**, **11**, and **12**) were found to be significantly active. This is the first report on phytochemical composition and biological activity of *Oparanthus teikiteetini*.

2. Results and discussion

The EtOAc extract from the leaves of *O. teikiteetini* increased the extracellular secretion of GLP-1 in STC-1 cells by $249 \pm 2\%$ when tested at a concentration of 30 $\mu\text{g}/\text{mL}$ (Supplem. S1). This extract was subjected to successive chromatographic separations leading to fifteen compounds (**1-15**) (Figure 1 and Supplem. S2), including two new dihydrobenzofuranes identified as (2R)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-5-ol (**1**) and (2S,3R)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-3,5-diol (**2**). Eight other coumaran derivatives were isolated and identified by careful comparison of their spectral data with those reported in the literature as tremetone (**3**) (Banskota et al., 1998; Bonner et al., 1961; Lee et al., 2010), 3-hydroxytremetone (**4**), 6-hydroxytremetone (**5**), 3,6-dihydroxytremetone (**6**), 12-hydroxytremetone (**7**), 3-hydroxytremetol (**8**), megapodiol (**9**), and 6-hydroxy-megapodiol (**10**) (Jarvis et al., 1986; Spring et al., 1991). According to optical rotation and comparison with data in literature, all the isolated 2-substituted dihydrobenzofuran derivatives were found to have a 2R

absolute configuration and the 3-OH, 2-substituted derivatives a 2S,3R configuration, which is in accordance with previous literature reports (Wang et al., 2016). A bibenzopyran derivative, jasopyran (**11**), was also obtained (Ahmed et al., 2004), together with four sesquiterpene lactones: costunolide (**12**) (Rao et al., 1958, 1960), dihydrocostunolide (**13**), asperilin (**14**) (Herz and Kagan, 1967; Herz and Viswanathan, 1964), and grandulin (**15**). The structure of the latter was wrongly reported as a constituent of *Inula grandis* (Nikonova and Nikonov, 1970; Nikonova and Nikonov, 1972). Therefore, the natural occurrence of grandulin is herein reported for the first time.

Compound **1** was isolated as colorless oil. Its UV spectrum presented maxima of absorption at 228 and 300 nm. Its molecular formula was determined to be C₁₁H₁₂O₂ on the basis of the observed peak at *m/z* 177.0909 [M+H]⁺, indicating six degrees of unsaturation. The ¹³C and ¹H NMR data displayed typical signals of a 2,3-dihydrobenzofuran ring, confirmed by HMBC correlations. The proton and carbon signals are shown in Table 1. The aromatic ring was shown to be hydroxylated in *para* (δC 150.9), and the furan ring substituted in C-2 (δC 85.4) by a methylethenyl group composed of one olefinic quaternary carbon (δC 144.7), one olefinic methine (δC 110.4), and one methyl (δC 15.9). The methylene signal observed in DEPT and ¹H spectrum was assigned to position 3 (δC 34.8; δH 3.25, dd, *J* = 15.7, 8.3 Hz; 2.96, dd, *J* = 15.7, 8.3 Hz). Thus compound **1** was identified as 2,3-dihydro-2-(1-methylethenyl)-5-benzofuranol. This compound has been previously reported as a synthetic intermediate in the synthesis of coumaranol derivatives (Schädel and Habicher, 2002), but is now reported for the first time as a natural product and named oparanol.

Compound **2** was obtained as slightly orange oil and presented a UV spectrum similar to the one of compound **1**. Its molecular formula was deduced to be C₁₁H₁₂O₃ (*m/z* 191.0707, [M-H]⁻). The ¹H and ¹³C NMR spectra of compound **2** were remarkably similar to those of compound **1**, confirming a 5-hydroxyl-benzofuran skeleton substituted by a methylethenyl group in C-2 (see Table 1 for ¹³C and ¹H data). The downfield values for C-3 (δC 76.6) indicated the presence of an hydroxyl group in position 3, confirmed by the absence of a methylene signal in the ¹H spectrum but the presence of an oxygenated methine signal at 5.02 (d, *J* = 4.3 Hz). The relative configuration was assumed to be *trans* on the basis of the small coupling constant observed between H-2 and H-3 (4.3 Hz), according to the Karplus equation and to literature (Zalkow et al., 1972). Therefore, **2** was elucidated as 2,3-dihydro-2-(1-methylethenyl)-benzofuran-3,5-diol and named 3-hydroxy-oparanol.

All compounds were evaluated for their capacity to stimulate GLP-1 secretion in an *in vitro* model of STC-1 cells in culture (Table 2). The dihydrobenzofuran derivative 12-hydroxy-tremetone (**7**) was found to be the most active resulting in a 3-fold increase in GLP-1 secretion in STC-1 cells (305 ± 26%). Jasopyran (**11**) and costunolide (**12**) were also found to contribute to the bioactivity of the extract, as they stimulated GLP-1 secretion by 218 ± 41% and 156 ± 39% respectively. Furthermore, none of the isolated compounds affected STC-1 cells viability at the tested concentration, reinforcing

their therapeutic potential. However, in order to confirm the potential of *O. teikiteetini* compounds as antidiabetic agents, further *in vitro* and *in vivo* assays are required to identify mechanisms of actions and to assess lack of toxicity. As *O. teikiteetini* is considered as a threatened species due to its extremely narrow distribution, alternative sourcing is mandatory. Chemical synthesis could be considered thanks to the rather simple structure of active constituents (Sangeeta and Deepti, 2017). Also, alternative natural sources could be used. Compound **7**, the most active constituent in our bioassay, has been previously reported from various *Helichrysum* species, already used for essential oil production (Valverde Lopez and Rodriguez Gonzalez, 1971; Zapesochnaya et al., 1990). Supercritical CO₂ extraction from *Helichrysum italicum* flowers can be performed to yield an extract containing up to 23% of compound **7** (Jerković et al., 2016), providing therefore another source to study in depth its therapeutic potential. This would enable the preservation of biodiversity while contributing to the development of potential new drugs for the management of type 2 diabetes.

3. Experimental

3.1. General experimental procedures

Optical rotations were measured on a Jasco P-2000 polarimeter (λ 589 nm, path length 1.0 cm). NMR experiments were conducted on a Bruker 500 MHz Avance II spectrometer equipped with a ¹³C/¹H cryoprobe. HRESIMS analyses were carried out on an Agilent 6520 Q-ToF mass spectrometer. Preparative HPLC was conducted on a Gilson 322 LC system using an Axia Phenomenex C18 column (100 mm × 21.2 mm). Mobile phase consisted of a mixture of acetonitrile (ACN) and water (H₂O) containing 0.05% v/v formic acid at a flow rate of 25 mL/min. Vacuum liquid chromatography (VLC) was performed using 40–60 μ m silica gel (Sigma Aldrich). Sephadex LH-20 (Sigma Aldrich) was used for gel filtration chromatography. Thin-layer chromatography (TLC) was performed on pre-coated silica gel plates (silica gel 60 F254, Merck). HPLC grade solvents were purchased from Sigma Aldrich.

3.2. Plant material

Fresh leaves (1.75 kg) of *Oparanthus teikiteetini* were collected in January 2015 in Nuku-Hiva, Marquesas Islands, French Polynesia, and identified by Dr Jean-François Butaud, botanist. The harvesting permit n°0923 was delivered from DIREN in November 2014. A voucher specimen (No CM1717_OT 01-2015) is deposited at the herbarium of the University of French Polynesia.

3.3. Extraction and isolation

The air dried leaves of *Oparanthus teikiteetini* (153.9 g) were crushed and extracted by maceration with EtOAc (100 mL/50 g, 3 x 3 hours). The filtrates were combined and evaporated to obtain a crude EtOAc extract (28.15 g). The EtOAc extract was fractionated using vacuum liquid chromatography

(150 g of silica 60 Å, 40-63 µm, 230-400 mesh), each fraction obtained by eluting with 300 mL of the following solvents: cyclohexane (c-Hex), c-Hex-CHCl₃ (1:1), CHCl₃, CHCl₃-EtOAc (75:25), CHCl₃-EtOAc (1:1), EtOAc and CH₃OH (500 mL) to afford seven fractions; F1 (0.71 g), F2 (0.66 g), F3 (6.86 g), F4 (14.18 g), F5 (2.47 g), F6 (1.09 g), and F7 (2.08 g). F3 (750 mg) was fractionated on Sephadex-LH 20 eluting with CHCl₃/CH₃OH (1:1) to obtain twelve sub fractions (F3S1-F3S12). Sub fraction S-10 (62.1 mg) was purified by preparative HPLC (20% ACN during 3 min, to 65% ACN in 12 min) to yield compound **12** (41.2 mg). Sub fraction S-11 (201.2 mg) was purified in the same conditions to afford compounds **3** (108.3 mg), **5** (24.9 mg), and **12** (40.9 mg). F4 (800 mg) was fractionated using Sephadex LH-20 CHCl₃/CH₃OH (1:1) to afford ten main sub fractions (F4S1-F4S10). F4-S9 (402.4 mg) was purified by preparative HPLC (20% ACN during 3 min, to 65% ACN in 12 min) to yield compounds **3** (91.9 mg), **12** (109.9 mg), and **13** (6.0 mg). Using the same conditions, compounds **1** (2.5 mg), **3** (64.8 mg), **5** (8.9 mg), **8** (2.5 mg), and **12** (10.7 mg) were obtained from sub fraction F4-S10 (133.9 mg). F5 (700 mg) was also chromatographed on Sephadex-LH 20 column eluting with CHCl₃/CH₃OH (30:70) to obtain eight sub fractions (F5S1-F5S8). Sub fraction F5-S7 (129.6 mg) was further purified by preparative HPLC (20% ACN during 3 min, to 65% ACN in 12 min) to afford compounds **7** (1.0 mg), **8** (5.5 mg), **11** (1.6 mg), **6** (1.0 mg), and **14** (2.6 mg). Sub fraction F5-S8 (38.7 mg) was also purified on Axia column (20% ACN during 3 min, 20 to 65% in 19 min, then 65 to 80% in 4 min) to yield **15** (17.0 mg), **9** (4.1 mg), and **8** (2.5 mg). F6 (800 mg) was first fractionated on Sephadex LH-20 eluting with CHCl₃/CH₃OH (30:70) to obtain seven sub fractions (F6S1-F6S7). Sub fraction F6S6 (120 mg) was subjected to preparative HPLC (35 to 65% ACN in 13 min, then to 100% ACN in 5 min, flow rate 15 mL/min) to afford compounds **2** (1.0 mg), **4** (8.0 mg), and **9** (23.1 mg). Sub fraction F6S7 (20.2 mg) led to compound **10** (1.1 mg) after preparative HPLC.

3.3.1. *(2R)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-5-ol (1)*

Colorless oil; $[\alpha]_D^{20}$ -102.5 (c 0.18, MeOH); UV (nm): 203, 228, 300; HRESIMS m/z 177.0909 [M+H]⁺, (calcd error -0.6 ppm); ¹H NMR and ¹³C NMR data: see Table 1.

3.3.2. *(2S,3R)-2-(prop-1-en-2-yl)-2,3-dihydro-1-benzofuran-3,5-diol (2)*

Slightly orange oil; $[\alpha]_D^{20}$ -97.2 (c 0.18, MeOH); UV (nm): 203, 228, 302; HRESIMS m/z 191.0707 [M-H]⁻, (calcd error -3.5 ppm); ¹H NMR and ¹³C NMR data: see Table 1.

3.3.3. *(3aR,8R,8aR,9aR)-8-hydroxy-5,8a-dimethyl-3-methylene-3a,4,4a,7,8,8a,9,9a-octahydro-naphtho[2,3-b]furan-2(3H)-one (15)*

White amorphous powder; $[\alpha]_D^{20}$ +45.9 (c 0.10, MeOH); UV (nm): 215; HRESIMS m/z 249.1480 $[M+H]^+$, (calcd error -2.1 ppm); ^1H NMR and ^{13}C NMR data: see Table 1.

3.4. Bioassays

3.4.1. GLP-1 secretion assay

GLP-1 secretion assays were carried out as described previously (Tsoukalas et al., 2016). Briefly, STC-1 cells were cultured at 37°C under a 5% CO₂ atmosphere in high glucose (4.5 g/L) complete Dulbecco's modified Eagle's medium (DMEM, supplemented with 10% non-heat-inactivated fetal bovine serum (FBS), penicillin 100 IU mL⁻¹, and streptomycin 100 IU mL⁻¹). Cells were passed at subconfluency every 3-4 days. Twenty-four hours prior induction, 10⁴ cells per well in 100 μL complete low glucose (1 g/L) DMEM were seeded in a 96-well plate. Prior to treatment, cells were washed two times with HBSS (Thermo Fischer 14025092), after addition of 100 μL HBSS they were returned back in the incubator for 30 min. The samples DMSO stock solutions were diluted at 100 μM in HBSS containing a constant DMSO concentration of 1%. Finally, 125 μL of the diluted solutions were applied to the cells for 2 hours at 37°C in a 5% CO₂ atmosphere. The GLP-1 content of 100 μL of the cell supernatant was then quantified in an ELISA assay (Merck Millipore, EGLP-35K) according to the manufacturer instructions. For each molecule the assay was performed in quadruplicate and results expressed as the percentage of the GLP-1 content secreted by cells treated with HBSS containing only 1% DMSO. For the statistical analysis, a one-way ANOVA with post hoc Dunnett test was performed (* $p_{\text{adj}} \leq 0.05$; *** $p_{\text{adj}} \leq 0.001$).

3.4.2. Cytotoxicity assay

For the image cytometry assay, the STC-1 cells after treatment with the molecules were incubated during 20 minutes with DMEM complete medium containing propidium iodide, Hoechst reagent, and calcein (1 μM each). After incubation, pictures of each well were taken with a Celigo Imaging Cytometer (Nexcelom Bioscience) at visible and fluorescent light and processed with the Celigo program in order to quantify the percentage of viable cells.

Acknowledgments

This work was financially supported by the Foundation for the Development of the Chemistry of Natural Products and their Applications (CNRS/Academy of Sciences in Paris). We gratefully acknowledge Nicolas Humbert, Dr Christian D. Muller, and Dr Julien Godet for assistance with microplate reading, image cytometry, and statistical analysis, respectively.

References

- Ahmed, B., Al-Howiriny, T. A., Al-Rehaily, A. J., Mossa, J. S., 2004. Two germacrane sesquiterpenes and a bibenzopyran from *Jasonia montana*. J. Saudi Chem. Soc. 8, 105-114.
- Banskota, A. H., Tezuka, Y., Prasain, J. K., Matsushige, K., Saiki, I., Kadota, S., 1998. Chemical constituents of Brazilian propolis and their cytotoxic activities. J. Nat. Prod. 61, 896-900.
- Bohlmann, F., Zdero, C., King, R. M., Robinson, H., 1980. New sesquiterpene lactones and other constituents from *Fitchia speciosa*. Phytochemistry 19, 1141-1143.
- Bonner, W. A., De, G. J. I., Bowen, D. M., Shah, V. R., 1961. Toxic constituents of white snakeroot. *Tetrahedron Lett.* 417-420.
- Florence, J., Stuessy, T. F., 1988. *Sertum polynesianum* 3 : un *Bidens* (Asteraceae) nouveau de l'île de Nukuhiva (Marquises, Polynésie Française). Bull. Mus. Natl. Hist. Nat., B, Adansonia 10, 121-125.
- Herz, W., Kagan, H. B., 1967. Determination of the absolute configuration of hydroxylated sesquiterpene lactones by Horeau's method of asymmetric esterification. J. Org. Chem. 32, 216-218.
- Herz, W., Viswanathan, N., 1964. Constituents of Iva species. II. The structures of asperilin and ivasperin, two new sesquiterpene lactones. J. Org. Chem. 29, 1022-1026.
- Jarvis, B. B., Pena, N. B., Cömezöglü, S. N., Rao, M. M., 1986. Non-trichothecenes from *Baccharis megapotamica*. Phytochemistry 25, 533-535.
- Jerković, I., Rajić, M., Marijanović, Z., Bilić, M., Jokić, S., 2016. Optimization of supercritical CO₂ extraction of dried *Helichrysum italicum* flowers by response surface methodology: GC-MS profiles of the extracts and essential oil. Sep. Sci. Technol. (Philadelphia, PA, U. S.) 51, 2925-2931.
- Kimball, R. T., Crawford, D. J., 2004. Phylogeny of Coreopsidae (Asteraceae) using ITS sequences suggests lability in reproductive characters. Mol. Phylogenet. Evol. 33, 127-139.
- Lee, S. T., Davis, T. Z., Gardner, D. R., Colegate, S. M., Cook, D., Green, B. T., Meyerholtz, K. A., Wilson, C. R., Stegelmeier, B. L., Evans, T. J., 2010. Tremetone and structurally related compounds in white snakeroot (*Ageratina altissima*): A plant associated with trembles and milk sickness. J. Agri. Food Chem. 58, 8560-8565.
- Nauck, M. A., Kleine, N., Orskov, C., Holst, J. J., Willms, B., Creutzfeldt, W., 1993. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741-744.
- Nauck, M. A., Holst, J. J., Willms, B., Schmiegel, W., 1997. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. Exp. Clin. Endocrinol. Diabet. 105, 187-195.
- Nicolaus, M., Brodl, J., Linke, R., Woerle, H. J., Goke, B., Schirra, J., 2011. Endogenous GLP-1 regulates postprandial glycemia in Humans: relative contributions of insulin, glucagon, and gastric emptying. J. Clin. Endocrinol. Metab. 96, 229-236.

Nikonova, L. P., Nikonov, G. K., 1970. Grandulin and grandicin - new sesquiterpene lactones from *Inula grandis*. Khim. Prir. Soed. 6, 133-134.

Nikonova, L. P., Nikonov, G. K., 1972. Structure of grandicin and grandulin. Khim. Prir. Soed. 5, 679-680.

Rao, A. S., Kelkar, G. R., Bhattacharyya, S. C., 1958. Costunolide, a new sesquiterpene lactone from costus root oil. Chem. Ind. 1359-1360.

Rao, A. S., Kelkar, G. R., Bhattacharyya, S. C., 1960. Terpenoids. XXI. Structure of costunolide, a new sesquiterpene lactone from Costus root oil. Tetrahedron 9, 275-283.

Ryding, O., Bremer, K., 1992. Phylogeny, distribution, and classification of the Coreopsidae (Asteraceae). Syst. Bot. 649-659.

Sangeeta, B., Deepti, R., 2017. Synthetic routes and biological activities of benzofuran and its derivatives: a review. Lett. Org. Chem. 14, 381-402.

Schädel, U., Habicher, W. D., 2002. Synthesis of coumaran-5-ols - new model compounds for bioantioxidants. Heterocycles 57, 1049-1055.

Shannon, R. K., Wagner, W. L., 1997. *Oparanthus* (Asteraceae, subtribe Coreopsidinae) revisited. Allertonia 7, 273-295.

Spring, O., Vargas, D., Fischer, N. H., 1991. Sesquiterpene lactones and benzofurans in glandular trichomes of three *Pappobolus* species. Phytochemistry 30, 1861-1867.

Tsoukalas, M., Muller, C. D., Lobstein, A., Urbain, A., 2016. Pregnane glycosides from *Cynanchum marnierianum* stimulate GLP-1 secretion in STC-1 cells. Planta Med. 82, 992-999.

Valverde Lopez, S., Rodriguez Gonzalez, B., 1971. Benzofuran derivative isolated from *Helichrysum stoechas*. An. Quim. 67, 879-885.

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., Holst, J. J., 2001. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50, 609-613.

Wang, Y.-M., Zhao, J.-Q., Zhou, S.-Y., Yang, J.-L., Yao, X.-J., Tao, Y.-D., Mei, L.-J., Shi, Y.-P., 2016. New sesquiterpenes and benzofuran derivatives from the aerial parts of *Asterothamnus centrali-asiaticus*. Tetrahedron 72, 4910-4917.

Zalkow, L. H., Keinan, E., Steindel, S., Kalyanaraman, A. R., Bertrand, J. A., 1972. On the absolute configuration of toxol at C-3. Vicinal H-H coupling constants in 2-alkyl-3-hydroxydihydrobenzofurans. Tetrahedron Lett. 13, 2873-2876.

Zapesochnaya, G. G., Dzyadevich T. V., Karasartov B. S. Phenolic compounds of *Helichrysum italicum*. Chem. Nat. Compd. 1990; 26: 342-343.

Table 1. ^1H and ^{13}C NMR data for compounds **1**, **2**, and **15** (methanol- d_4 , δ in ppm, J in Hz, 500 MHz for ^1H NMR, 125 MHz for ^{13}C NMR).

| position | 1 | | 2 | | 15 | |
|----------|---------------------|--|---------------------|----------------------------|---------------------|----------------------|
| | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} |
| 1 | | | | | 121.4 | 5.38 (m) |
| 2 | 85.4 | 5.07 (t, 8.3) | 93.4 | 4.75 (d, 4.3) | 32.1 | 2.38 (m) 2.33 (m) |
| 3 | 34.8 | 3.25 (dd, 15.7, 8.3) 2.96 (dd, 15.7, 8.3) | 76.6 | 5.02 (d, 4.3) | 77.4 | 3.64 (m) |
| 4 | 113.6 | 6.63 (d, 1.5) | 111.6 | 6.81 (m) | 40.7 | - |
| 5 | 150.9 | - | 151.2 | - | 34.2 | 2.05 (m) 1.35 (m) |
| 6 | 111.6 | 6.52 (m) | 116.6 | 6.69 (m) | 82.1 | 4.04 (t) |
| 7 | 108.3 | 6.51 (m) | 109.4 | 6.66 (m) | 51.0 | 2.59 (br s) |
| 8 | 152.9 | - | 153.2 | - | 20.7 | 2.12 (m) 1.68 (m) |
| 9 | 127.3 | - | 128.7 | - | 50.8 | 2.42 (br d, 11.9) |
| 10 | 144.7 | - | 142.7 | - | 133.2 | - |
| 11 | 110.4 | 5.04 (s) 4.86 (s) | 110.7 | 5.06 (m) 4.89 (overlap) | 139.6 | - |
| 12 | 15.9 | 1.74 (s) | 16.2 | 1.79 (s) | 171.4 | - |
| 13 | | | | | 115.6 | 6.03 (s) 5.52 (s) |
| 14 | | | | | 22.2 | 1.84 (s) |
| 15 | | | | | 9.96 | 0.89 (s) |

Table 2. Glucagon-like peptide-1 secretagogue activity and cell viability induced by compounds **1-15** (tested at 100 μ M on STC-1 cells).

| Compound | GLP-1 secretion stimulation (%) | Cell viability (%) |
|-----------------------|---------------------------------|--------------------|
| control | 100 \pm 10 | 96 \pm 1 |
| 7^a | 305 \pm 26 | 96 \pm 1 |
| 11^a | 218 \pm 41 | 97 \pm 1 |
| 12^b | 156 \pm 39 | 94 \pm 1 |
| 15 | 145 \pm 15 | 96 \pm 1 |
| 1 | 121 \pm 9 | 97 \pm 1 |
| 10 | 109 \pm 11 | 95 \pm 1 |
| 14 | 104 \pm 6 | 97 \pm 1 |
| 4 | 104 \pm 16 | 91 \pm 2 |
| 13 | 102 \pm 20 | 95 \pm 2 |
| 3 | 101 \pm 20 | 96 \pm 1 |
| 9 | 100 \pm 16 | 95 \pm 1 |
| 6 | 94 \pm 9 | 96 \pm 1 |
| 2 | 93 \pm 25 | 91 \pm 2 |
| 8 | 91 \pm 13 | 96 \pm 1 |
| 5 | 81 \pm 9 | 97 \pm 1 |

Data are expressed as the mean \pm SD of four independent experiments.

^a *** $p_{\text{adj}} < 0.001$

^b * $p_{\text{adj}} < 0.05$

Figure 1. Structures of compounds **1-2** and **15**.

